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Major advances in the treatment of cardiovascular disease
and better implementation of aggressive risk factor reduc-
tion strategies have resulted in signiﬁcant declines in overall
cardiovascular mortality over the past 3 decades (1). Despite
these advances, the rate of sudden cardiac death (SCD)
has remained largely unchanged over the same period (2).
SCD continues to account for >50% of all cardiovascular
deaths and up to 20% of all deaths (3). Furthermore,
survival following an out-of-hospital cardiac arrest remains
dismal despite improvements in resuscitative care (4). As
such, substantial reductions in the incidence of SCD will
require signiﬁcant improvements in primary prevention
strategies.
See page 2112
The current approach to prevention of SCD involves the
placement of an implantable cardiac-deﬁbrillator (ICD) in
high-risk individuals. For such an approach to be effective, it
needs to be applied to populations at elevated risk for SCD.
However, identifying those at elevated risk has proven to be
problematic (3). The best-known predictors of SCD are the
degree of left ventricular systolic dysfunction and the
severity of heart failure symptoms (5). In such patients, the
use of ICD therapy has demonstrated clear survival beneﬁts
(6,7). Unfortunately, the use of these criteria to reduce SCD
incidence in the general population has signiﬁcant limita-
tions. In fact, most SCD victims in the community do not
have a pre-existing history of depressed ejection fraction or
a clinical history of heart failure (8–10). As such, our current*Editorials published in the Journal of the American College of Cardiology reﬂect the
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relevant to the contents of this paper to disclose.strategy fails to identify and affect the vast majority of
individuals who suffer a SCD event.
Signiﬁcant efforts have been made to improve risk
prediction models for SCD in the general population by
incorporating additional clinical characteristics (11–13).
Coronary artery disease (CAD) is the most common
substrate underlying SCD, noted in up to 75% of cases (3).
As such, it is not surprising that CAD and risk factors for
CAD (hypertension, hypercholesterolemia, diabetes, kidney
disease, obesity, and smoking) are also predictive of SCD
(3). Unfortunately, these risk factors are also strongly
associated with competing causes of cardiac death. As such,
their ability to improve patient selection for device-based
therapy is limited. ICD therapy speciﬁcally targets SCD
events. The utilization of screening markers that are also
associated with competing modes of death signiﬁcantly
limits the effectiveness of deﬁbrillation therapy, which only
targets SCD.
To improve the performance of prediction models and to
identify patients who would receive the maximum beneﬁt
from ICD therapy, we need to identify markers that
speciﬁcally predict SCD. The identiﬁcation of markers
speciﬁcally associated with SCD may also further improve
our understanding of the complex and poorly understood
pathophysiology of this disease process.
In this issue of the Journal, Hussein et al. (14) report
their ﬁndings of a signiﬁcant, graded association between
cardiac troponin T levels, measured by a highly set sensitive
assay (hsTnT), and the risk of SCD in a large community-
based population. Most of the participants in the study were
older with an average age of 72.8 years at the time of
enrollment (range 65 to 100). They were followed for
a median of 13.1 years. The association between hsTnT
levels and the risk of SCD was ﬁrst tested using hsTnT as
a continuous variable. Subsequently, 3 groups (low-, inter-
mediate-, and high-risk) were identiﬁed using the Cox
proportional hazard ratios of SCD for each decile of
detectable hsTnT compared with those for participants with
undetectable levels. Overall, higher levels of hsTnT were
associated with an increased risk for SCD (unadjusted
hazard ratio [HR] for þ1 log hsTnT: 2.04; 95% conﬁdence
interval [CI]: 1.78 to 2.34). The incidence of SCD was
3.4%, 6.6%, and 8.7% for the low-, intermediate-, and
high-risk groups (fully adjusted HR: 1 vs. 1.55 vs. 1.89,
respectively; p ¼ 0.005).
The association between hsTnT and SCD was attenuated
after adjusting for other clinical risk factors as well as low
ejection fraction, heart failure, and myocardial infarction
(HR: 1.26; 95% CI: 1.05 to 1.62). This ﬁnding suggests that
hsTnT may serve as a marker for these other conditions and
thus co-segregate them. However, the fact that the associ-
ation persisted after making these adjustments implies that
hsTnT may also either directly inﬂuence the risk of SCD or
serve as a marker for SCD that is more strongly related to
the underlying pathophysiology of SCD than this group of
covariates is. Establishing with better clarity, the cause and
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gy of SCD will require further investigation. The data
presented by Hussein et al. (14) is an important ﬁrst step in
establishing this connection.
The hypothesis that hsTnT would carry a speciﬁc asso-
ciation with an elevated risk of SCD appears very plausible.
As the investigators point out, subclinical cardiac myocyte
injury, as reﬂected by low levels of circulating hsTnT, may
provide the anatomical substrate for scar-related electrical
re-entry, which would support and propagate lethal ar-
rhythmias. Low levels of circulating hsTnT may also be an
indicator of ongoing subclinical myocardial inﬂammation
that may result in cell membrane instability. This instability
could theoretically result in increased automaticity, trig-
gered activity or result in a dispersion of phase 3 refracto-
riness that could pre-dispose the patient to the sudden
development of malignant arrhythmias. The intriguing
prospect of using biomarkers is their presumptive ability to
detect processes that may pre-dispose the patient to a risk
for SCD prior to the onset of clinically overt cardiovascular
disease. Myocardial inﬂammation, cardiac remodeling, and
scar formation could theoretically be detected and ad-
dressed at very early stages of the disease process when the
opportunity to intervene would have the greatest impact on
survival.
Unfortunately, despite the association, the data presented
do not provide any information to determine whether
hsTnT would help improve SCD prediction models and
the investigators acknowledge that this was not the aim
of the study. To establish its usefulness in predicting
SCD, a statistically signiﬁcant improvement in discrimi-
nation (C-index) after adding hsTnT to current prediction
models would need to be demonstrated. Attempts to
do so with other clinical markers associated with SCD
have been limited to mostly nonsigniﬁcant improvements
in the risk prediction model (11). This is likely due in
part to the fact that these markers are not speciﬁc to
SCD and are associated with an increased risk for cardio-
vascular death as well as all-cause mortality. It appears
as if hsTnT may be vulnerable to this limitation. As pre-
sented in Hussein et al.’s paper, hsTnT was also associated
with the risk of all-cause mortality and nonsudden
cardiovascular mortality. Despite the fact that the associa-
tion between hsTnT and SCD appeared to be stronger
with a higher HR, a deﬁnitive conclusion regarding the
strength of the association could not be made as the CI
overlapped.
Even if hsTnT is unlikely to improve risk prediction
models for SCD, this biomarker may be useful as a screening
tool for the general population, where access to traditional
screening with echocardiography is often difﬁcult and cost-
prohibitive. It is possible that TnT could play a role in
identifying patients who require further evaluation and risk
stratiﬁcation. The likely problem with this strategy, however,
is that the highly sensitive assay used to assess for TnT
may be too sensitive. In the report presented by Husseinet al. (14), 67% of patients (2,989 of 4,431) had baseline
detectable levels of hsTnT. Furthermore, only 46% of the
population had a level <5.0 pg/ml and fell into a low-
risk category. This suggests that if applied as a solitary
screening tool to a large, older, general population, follow-up
assessment would be necessary in over 50% of those
screened. It is possible that these ﬁndings are skewed by the
fact that the marker was assessed in an older population that
carried a more signiﬁcant burden of cardiovascular risk
factors. Its utility as a screening tool in a younger healthier
patient population may be more plausible but requires
further investigation. Due to the high prevalence of elevated
hsTnT, this biomarker may be more useful for its neg-
ative predictive value. Of the 2,039 subjects with hsTnT
5.0 pg/ml, only 69 patients had a SCD event. Using this
cutoff, the negative predictive value of a low level of hsTnT
is 96.6%.
In summary, Hussein et al. (14) present novel work
that demonstrates an association between hsTnT and SCD.
The clinical applications of such a ﬁnding have yet to be
established and will require further investigation. Although
hsTnT was also associated with the risk of all-cause mor-
tality and nonsudden cardiovascular mortality, it appears to
potentially have a stronger association with SCD. This
ﬁnding is signiﬁcant as it suggests that hsTnT levels may be
directly related to the underlying pathophysiology of SCD.
A better understanding of the pathophysiology of SCD
is critical as we continue to look for novel therapeutic
prevention approaches.Reprint requests and correspondence: Dr. Oussama Wazni, Out
Patient Department, Section of Cardiac Electrophysilogy, Cleve-
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